What’s in Ironwood Pharmaceuticals, Inc. (IRWD) After Forming Head & Shoulders Pattern?

September 16, 2018 - By Robert Shackelford

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Investors sentiment increased to 1.03 in 2018 Q2. Its up 0.33, from 0.7 in 2018Q1. It is positive, as 19 investors sold Ironwood Pharmaceuticals, Inc. shares while 43 reduced holdings. 22 funds opened positions while 42 raised stakes. 146.28 million shares or 2.74% less from 150.40 million shares in 2018Q1 were reported.
Mackay Shields Ltd Liability Corporation reported 48,469 shares stake. Shell Asset Mgmt owns 13,094 shares for 0.01% of their portfolio. Bailard owns 28,500 shares for 0.03% of their portfolio. Platinum Mngmt Ltd invested 0.04% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Swiss National Bank & Trust invested 0.01% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Morgan Stanley, New York-based fund reported 361,036 shares. Alps Advsrs reported 150,030 shares. Atika Capital Mngmt Lc invested in 164,000 shares. Bvf Il reported 606,715 shares. Qs Limited Company stated it has 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Aperio Group Inc Limited Liability Company has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Chicago Equity Prtn Ltd Company owns 244,275 shares or 0.14% of their US portfolio. Broderick Brian C has invested 2.64% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Geode Cap Mngmt Ltd Llc owns 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 1.42M shares. Granahan Invest Mgmt Ma holds 0.6% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 520,888 shares.

Since June 5, 2018, it had 0 insider buys, and 9 selling transactions for $4.91 million activity. Gilbert Halley E also sold $583,632 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares. Currie Mark G sold 130,000 shares worth $2.40 million. 1,500 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares with value of $26,430 were sold by McHugh Julie. On Friday, July 6 MCCOURT Thomas A sold $600,000 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 30,000 shares. Consylman Gina also sold $3,423 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares.

The stock of Ironwood Pharmaceuticals, Inc. (IRWD) formed H&S with $16.81 target or 8.00 % below today’s $18.27 share price. The 5 months Head & Shoulders indicates high risk for the $2.80 billion company. It was reported on Sep, 16 by Faxor.com. If the $16.81 price target is reached, the company will be worth $223.84M less.
Head-and-shoulders are one of the best chart patterns to trade. They work in bear and bull markets and according to many researchers have very low failure rate. Even thought they have high pullback rate, such patters usually provide good risk-reward entry opportunities. The percentage of stocks meeting price targets is 55%.

The stock increased 0.44% or $0.08 during the last trading session, reaching $18.27. About 612,412 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 14.01% since September 16, 2017 and is uptrending. It has underperformed by 1.61% the S&P500.

Analysts await Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report earnings on November, 1. They expect $-0.19 earnings per share, down 5.56 % or $0.01 from last year’s $-0.18 per share. After $-0.28 actual earnings per share reported by Ironwood Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -32.14 % EPS growth.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 7 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Ironwood Pharma had 9 analyst reports since April 19, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, May 31 by Mizuho. Mizuho upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, May 2 to “Buy” rating. The firm has “Market Perform” rating given on Wednesday, July 18 by Cowen & Co. The firm has “Outperform” rating by Wells Fargo given on Thursday, May 31. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Underweight” rating by Morgan Stanley on Wednesday, May 9. Berenberg initiated Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Thursday, April 19 with “Buy” rating. The firm earned “Outperform” rating on Thursday, August 9 by Wells Fargo.

More news for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were recently published by: Bizjournals.com, which released: “Ahead of split, Ironwood gets FDA fast track status for heart drug” on September 13, 2018. Streetinsider.com‘s article titled: “Ironwood Pharma (IRWD) Announces FDA Fast Track Designation for Praliciguat for Heart Failure” and published on September 13, 2018 is yet another important article.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.80 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.